Works matching DE "PROGRAMMED death-ligand 1"
Results: 3525
Selective Degradation of PD‐L1 in Cancer Cells by Enzyme‐Instructed Self‐Assembly.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy.
- Published in:
- Advanced Functional Materials, 2023, v. 33, n. 16, p. 1, doi. 10.1002/adfm.202214499
- By:
- Publication type:
- Article
Less is More: Preorganization Leads to Better Tumor Retention and Therapeutic Efficacy.
- Published in:
- Advanced Functional Materials, 2022, v. 32, n. 49, p. 1, doi. 10.1002/adfm.202206969
- By:
- Publication type:
- Article
A Versatile 980 nm Absorbing Aggregation‐Induced Emission Luminogen for NIR‐II Imaging‐Guided Synergistic Photo‐Immunotherapy Against Advanced Pancreatic Cancer.
- Published in:
- Advanced Functional Materials, 2022, v. 32, n. 36, p. 1, doi. 10.1002/adfm.202205371
- By:
- Publication type:
- Article
Inosine‐Based Supramolecular Hydrogel for Highly Efficient PD‐L1 Blockade Therapy via Mediating CD8<sup>+</sup> T Cells (Adv. Funct. Mater. 33/2022).
- Published in:
- Advanced Functional Materials, 2022, v. 32, n. 33, p. 1, doi. 10.1002/adfm.202204273
- By:
- Publication type:
- Article
Inosine‐Based Supramolecular Hydrogel for Highly Efficient PD‐L1 Blockade Therapy via Mediating CD8<sup>+</sup> T Cells.
- Published in:
- Advanced Functional Materials, 2022, v. 32, n. 33, p. 1, doi. 10.1002/adfm.202204273
- By:
- Publication type:
- Article
Boosting Tumor Immunotherapy by Bioactive Nanoparticles via Ca<sup>2+</sup> Interference Mediated TME Reprogramming and Specific PD‐L1 Depletion.
- Published in:
- Advanced Functional Materials, 2022, v. 32, n. 24, p. 1, doi. 10.1002/adfm.202201275
- By:
- Publication type:
- Article
Selective Degradation of PD‐L1 in Cancer Cells by Enzyme‐Instructed Self‐Assembly.
- Published in:
- Advanced Functional Materials, 2021, v. 31, n. 45, p. 1, doi. 10.1002/adfm.202102505
- By:
- Publication type:
- Article
Inspired Epigenetic Modulation Synergy with Adenosine Inhibition Elicits Pyroptosis and Potentiates Cancer Immunotherapy.
- Published in:
- Advanced Functional Materials, 2021, v. 31, n. 20, p. 1, doi. 10.1002/adfm.202100007
- By:
- Publication type:
- Article
Implantable Bioresponsive Nanoarray Enhances Postsurgical Immunotherapy by Activating Pyroptosis and Remodeling Tumor Microenvironment.
- Published in:
- Advanced Functional Materials, 2020, v. 30, n. 51, p. 1, doi. 10.1002/adfm.202005747
- By:
- Publication type:
- Article
Near‐Infrared Triggered Cascade of Antitumor Immune Responses Based on the Integrated Core–Shell Nanoparticle.
- Published in:
- Advanced Functional Materials, 2020, v. 30, n. 50, p. 1, doi. 10.1002/adfm.202000335
- By:
- Publication type:
- Article
Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
- Published in:
- Journal of Computer-Aided Molecular Design, 2020, v. 34, n. 8, p. 897, doi. 10.1007/s10822-020-00306-0
- By:
- Publication type:
- Article
The roles of PD-L1 in the various stages of tumor metastasis.
- Published in:
- Cancer & Metastasis Reviews, 2024, v. 43, n. 4, p. 1475, doi. 10.1007/s10555-024-10189-4
- By:
- Publication type:
- Article
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma.
- Published in:
- Cancer & Metastasis Reviews, 2024, v. 43, n. 3, p. 889, doi. 10.1007/s10555-024-10174-x
- By:
- Publication type:
- Article
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
- Published in:
- Cancer & Metastasis Reviews, 2021, v. 40, n. 2, p. 537, doi. 10.1007/s10555-021-09972-4
- By:
- Publication type:
- Article
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.
- Published in:
- World Journal of Urology, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s00345-024-05392-5
- By:
- Publication type:
- Article
Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.
- Published in:
- European Journal of Clinical Pharmacology, 2025, v. 81, n. 1, p. 139, doi. 10.1007/s00228-024-03777-4
- By:
- Publication type:
- Article
The sound and surprise: overlapping meta-analyses on the topic of safety and efficacy of PD-1 and PD-L1 inhibitors in the treatment of non-small cell lung cancer.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 12, p. 1665, doi. 10.1007/s00228-023-03577-2
- By:
- Publication type:
- Article
Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection.
- Published in:
- Digestive Diseases, 2024, v. 42, n. 1, p. 53, doi. 10.1159/000534535
- By:
- Publication type:
- Article
A Rare Case of NUT Carcinoma of the Thyroid.
- Published in:
- JCEM Case Reports, 2024, v. 2, n. 3, p. 1, doi. 10.1210/jcemcr/luae037
- By:
- Publication type:
- Article
Iatrogenic Pituitary Shutdown: A Rare Adverse Event of Programmed Cell Death-Ligand 1 Inhibitor.
- Published in:
- JCEM Case Reports, 2024, v. 2, n. 1, p. 1, doi. 10.1210/jcemcr/luad157
- By:
- Publication type:
- Article
Redefining Treatment Paradigms in Metastatic Castration-resistant Prostate Cancer: A Comprehensive Analysis of Cabozantinib and Atezolizumab Based on the CONTACT-02 Study Results.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2024, v. 20, n. 2, p. 45, doi. 10.17925/OHR.2024.20.2.3
- By:
- Publication type:
- Article
Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2023, v. 19, n. 1, p. 22, doi. 10.17925/OHR.2023.19.1.22
- By:
- Publication type:
- Article
Coffee extracts and caffeine upregulate the expression of the immune checkpoint factors, PD‑1 and PD‑L1.
- Published in:
- International Journal of Functional Nutrition, 2024, v. 5, n. 1, p. N.PAG, doi. 10.3892/ijfn.2024.36
- By:
- Publication type:
- Article
Weakly supervised deep learning to predict recurrence in low-grade endometrial cancer from multiplexed immunofluorescence images.
- Published in:
- NPJ Digital Medicine, 2023, v. 6, n. 1, p. 1, doi. 10.1038/s41746-023-00795-x
- By:
- Publication type:
- Article
A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors.
- Published in:
- European Clinical Respiratory Journal, 2023, v. 10, p. 1, doi. 10.1080/20018525.2023.2194162
- By:
- Publication type:
- Article
The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study.
- Published in:
- European Clinical Respiratory Journal, 2021, v. 8, n. 1, p. 1, doi. 10.1080/20018525.2021.1984375
- By:
- Publication type:
- Article
Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.
- Published in:
- Turkish Journal of Medical Sciences, 2024, v. 54, n. 4, p. 735, doi. 10.55730/1300-0144.5843
- By:
- Publication type:
- Article
Role of PD-1/PD-L1-mediated tumour immune escape mechanism and microsatellite instability in the BCG failure of high-grade urothelial carcinomas.
- Published in:
- Turkish Journal of Medical Sciences, 2022, v. 52, n. 6, p. 1802, doi. 10.55730/1300-0144.5526
- By:
- Publication type:
- Article
The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.
- Published in:
- Turkish Journal of Medical Sciences, 2022, v. 52, n. 4, p. 1050, doi. 10.55730/1300-0144.5407
- By:
- Publication type:
- Article
PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
- Published in:
- Turkish Journal of Medical Sciences, 2022, v. 52, n. 4, p. 1013, doi. 10.55730/1300-0144.5403
- By:
- Publication type:
- Article
The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
- Published in:
- Turkish Journal of Medical Sciences, 2021, v. 51, n. 1, p. 204, doi. 10.3906/sag-2004-61
- By:
- Publication type:
- Article
The yeast also rises! PD-L1 dampens inflammation linked to fungal infections.
- Published in:
- Science Immunology, 2024, v. 9, n. 98, p. N.PAG, doi. 10.1126/sciimmunol.adr9663
- By:
- Publication type:
- Article
Separation anxiety: Splitting PD-L1 from CD80 suppresses autoimmunity.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Antigen cross-presentation in young tumor-bearing hosts promotes CD8<sup>+</sup> T cell terminal differentiation.
- Published in:
- Science Immunology, 2022, v. 7, n. 68, p. 1, doi. 10.1126/sciimmunol.abf6136
- By:
- Publication type:
- Article
Immunotheraphy for Breast Cancer by Immune Check Point Inhibitors (Pd-1 & Pd-L1) using CNN for Image Analysis in Deep Learning.
- Published in:
- Grenze International Journal of Engineering & Technology (GIJET), 2024, v. 10, n. 2,Part 4, p. 5745
- By:
- Publication type:
- Article
Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011−2021.
- Published in:
- Oncology & Therapy, 2023, v. 11, n. 3, p. 343, doi. 10.1007/s40487-023-00234-7
- By:
- Publication type:
- Article
Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
- Published in:
- Oncology & Therapy, 2023, v. 11, n. 2, p. 185, doi. 10.1007/s40487-023-00226-7
- By:
- Publication type:
- Article
PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.
- Published in:
- Archive of Clinical Cases, 2021, v. 8, n. 1, p. 14, doi. 10.22551/2021.30.0801.10179
- By:
- Publication type:
- Article
Fighting disease at 83 years old: SARS-CoV-2 survival and response to anti-PD-1 therapy in PD-L1 negative adenocarcinoma of the lung – case report.
- Published in:
- Oncolog-Hematolog, 2022, n. 58, p. 32
- By:
- Publication type:
- Article
Neoadjuvant treatment in triple-negative breast cancer.
- Published in:
- Oncolog-Hematolog, 2020, n. 52, p. 40
- By:
- Publication type:
- Article
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- Vaccines, 2024, v. 12, n. 5, p. 474, doi. 10.3390/vaccines12050474
- By:
- Publication type:
- Article
Usp22 Deficiency Leads to Downregulation of PD-L1 and Pathological Activation of CD8 + T Cells and Causes Immunopathology in Response to Acute LCMV Infection.
- Published in:
- Vaccines, 2023, v. 11, n. 10, p. 1563, doi. 10.3390/vaccines11101563
- By:
- Publication type:
- Article
PD-L1 Is Involved in the Development of Non-Hodgkin's Lymphoma by Mediating Circulating Lymphocyte Apoptosis.
- Published in:
- Vaccines, 2023, v. 11, n. 9, p. 1474, doi. 10.3390/vaccines11091474
- By:
- Publication type:
- Article
Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves.
- Published in:
- Vaccines, 2023, v. 11, n. 3, p. 559, doi. 10.3390/vaccines11030559
- By:
- Publication type:
- Article
A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.
- Published in:
- Vaccines, 2022, v. 10, n. 7, p. N.PAG, doi. 10.3390/vaccines10071092
- By:
- Publication type:
- Article
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.
- Published in:
- Vaccines, 2021, v. 9, n. 5, p. 422, doi. 10.3390/vaccines9050422
- By:
- Publication type:
- Article
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.
- Published in:
- Vaccines, 2020, v. 8, n. 4, p. 703, doi. 10.3390/vaccines8040703
- By:
- Publication type:
- Article
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
- Published in:
- Vaccines, 2020, v. 8, n. 2, p. 203, doi. 10.3390/vaccines8020203
- By:
- Publication type:
- Article
CMTM4 和 PD-L1蛋白在胰腺癌组织中的表达及其与临床病理特征的关系.
- Published in:
- Progress in Modern Biomedicine, 2024, v. 24, n. 13, p. 2478, doi. 10.13241/j.cnki.pmb.2024.13.014
- By:
- Publication type:
- Article